Clinical observational studies
Contact: PD Dr. med. Martin Klietz
Staff members:
- Prof. Dr. med. C. Schrader
- PD Dr. med. Martin Klietz
- Dr. med. Meret Koroni Huber
- Doctor Sophia Marie Rogozinski
Clinical research into idiopathic Parkinson's disease and atypical Parkinson's syndromes, such as multisystem atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), is carried out in our Neurology Clinical Department at Hannover Medical School at an internationally well-networked level.
We work closely with, among others:
- The German Center for Neurodegenerative Diseases
- the German Society for Parkinson's and Movement Disorders
- the International Movement Disorders Society
The issues we are investigating include
- Optimization of early diagnosis
- Development of biomarkers for early diagnosis and monitoring of progression
- Development of modern imaging techniques
- Development of clinical scales for monitoring the course of the disease
- Prediction of the course of the disease
We coordinate the following large observational studies:
ProPSP and Describe PSP study
The ProPSP study and the DESCRIBE PSP study coordinated by us are two independent national observational studies on research into progressive supranuclear palsy (PSP). In the ProPSP and DESCRIBE PSP studies, we prospectively collect clinical data and biomaterials from patients with PSP at 12-month intervals. The ProPSP network consists of 26 academic centers in Germany. The Describe PSP network consists of 8 centers that are members of the German Center for Neurodegenerative Diseases.
Hannover TrajectoryCohort- Parkinsonism: HATCH-P
As part of our HATCH-P biobank at the MHH, we prospectively and longitudinally collect clinical data and biomaterials from patients with early atypical or idiopathic Parkinson's syndrome. The patients are followed up longitudinally every 12 months. Blood components (serum, plasma, PBMC), CSF, saliva and genetic data (DNA, RNA) will be collected and used for research purposes. In addition, patients will be characterized using standard clinical scales to define symptom burden. Imaging data from clinical care (MRI and nuclear medicine diagnostics e.g. FDG-PET) will be included in the study if available.
Contact:
PD Dr. med. Martin Klietz
Senior consultant
Clinical Department of Neurology
Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hanover
Phone: 0511 - 532 5350
Email: Klietz.Martin@mh-hannover.de
Publications: